Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage

• Published in: FEBS open bio Vol. 11; no. 3; pp. 782 - 792
• Main Authors: Hong, Yuan, Feng, Yingcai, Sun, Hanzi, Zhang, Bo, Wu, Hongfu, Zhu, Qing, Li, Yucheng, Zhang, Tong, Zhang, Yilu, Cui, Xinxin, Li, Zhuo, Song, Xiaomin, Li, Kang, Liu, Mike, Liu, Ye
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.03.2021; John Wiley and Sons Inc; Wiley
• Subjects: Animals; Antibodies; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacology; Antigens; Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - pharmacology; Antitumor activity; anti‐PD‐1 antibody; Apoptosis; BGB‐A317; Binding Sites; Cancer immunotherapy; Cancer therapies; carcinoma; Cell death; Cloning; dissociation; epitope mapping; Epitopes; FDA approval; Hodgkin disease; Hodgkin's lymphoma; Humans; Immune checkpoint; Immunotherapy; Laboratory animals; Ligands; Lung cancer; Lymphocytes; Lymphoma; mechanism of action; Melanoma; Melanoma, Experimental - drug therapy; Melanoma, Experimental - genetics; Mice; Mice, Transgenic; Models, Molecular; Monoclonal antibodies; Mutagenesis; Mutation; PD-L1 protein; PD‐1; Peptides; Plasmids; programmed cell death; Programmed Cell Death 1 Receptor - chemistry; Programmed Cell Death 1 Receptor - genetics; Programmed Cell Death 1 Receptor - metabolism; Protein Binding - drug effects; Protein Conformation; Protein Domains; Protein expression; Proteins; Software; Statistical analysis; structural biology; Structure-function relationships; Surface Plasmon Resonance; Targeted cancer therapy; tislelizumab; Transgenic animals; Tumors; Urothelial carcinoma; Xenograft Model Antitumor Assays; New York; United States > US; China; anti-PD-1 antibody; BGB-A317; tislelizumab; PD-1; epitope mapping
• ISSN: 2211-5463; 2211-5463
• DOI: 10.1002/2211-5463.13102

Programmed cell death protein 1 (PD‐1), an immune checkpoint receptor expressed by activated T, B, and NK cells, is a well‐known target for cancer immunotherapy. Tislelizumab (BGB‐A317) is an anti‐PD‐1 antibody that has recently been approved for treatment of Hodgkin's lymphoma and urothelial carcinoma. Here, we show that tislelizumab displayed remarkable antitumor efficacy in a B16F10/GM‐CSF mouse model. Structural biology and Surface plasmon resonance (SPR) analyses revealed unique epitopes of tislelizumab, and demonstrated that the CC′ loop of PD‐1, a region considered to be essential for binding to PD‐1 ligand 1 (PD‐L1) but not reported as targeted by other therapeutic antibodies, significantly contributes to the binding of tislelizumab. The binding surface of tislelizumab on PD‐1 overlaps largely with that of the PD‐L1. SPR analysis revealed the extremely slow dissociation rate of tislelizumab from PD‐1. Both structural and functional analyses align with the observed ability of tislelizumab to completely block PD‐1/PD‐L1 interaction, broadening our understanding of the mechanism of action of anti‐PD‐1 antibodies. We evaluated the antitumor efficacy of tislelizumab (BGB‐A317), an approved anti‐PD‐1 antibody. Its critical epitopes were investigated by both structural biology and SPR studies, and the CC′ loop of PD‐1 was discovered to be a novel targetable region for anti‐PD‐1 antibodies. The unique epitopes and slow dissociation rate of tislelizumab contribute to its complete blocking activity to PD‐L1.